An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 050689
Company: PFIZER

Products on NDA 050689

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
MYCOBUTIN	RIFABUTIN	150MG	CAPSULE;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 050689

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
12/23/1992	ORIG-1	Approval	Type 1 - New Molecular Entity	PRIORITY; Orphan		Label is not available on this site.

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/20/2024	SUPPL-27	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050689s027lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/050689Orig1s027ltr.pdf
09/15/2021	SUPPL-26	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s026lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050689Orig1s026ltr.pdf
03/08/2021	SUPPL-25	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s025lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050689Orig1s025ltr.pdf
07/01/2015	SUPPL-22	Labeling-Package Insert	Label (PDF) Letter (PDF)	Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050689s022lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/050689Orig1s022ltr.pdf
11/13/2014	SUPPL-18	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050689Orig1s018lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/050689Orig1s018ltr.pdf
05/14/2008	SUPPL-16	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/050689s016ltr.pdf
01/29/2001	SUPPL-14	Manufacturing (CMC)-Control		Label is not available on this site.
11/09/2001	SUPPL-13	Labeling	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/50689s13ltr.pdf
01/15/1999	SUPPL-12	Manufacturing (CMC)		Label is not available on this site.
11/09/2001	SUPPL-11	Labeling	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50689s11s13lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/50689s13ltr.pdf
09/13/1996	SUPPL-10	Manufacturing (CMC)		Label is not available on this site.
11/03/1995	SUPPL-8	Labeling		Label is not available on this site.
01/11/1996	SUPPL-7	Manufacturing (CMC)-Packaging		Label is not available on this site.
06/06/1994	SUPPL-6	Manufacturing (CMC)-Control		Label is not available on this site.
05/31/1994	SUPPL-5	Manufacturing (CMC)-Control		Label is not available on this site.
09/08/1995	SUPPL-4	Manufacturing (CMC)-Expiration Date		Label is not available on this site.
06/22/1993	SUPPL-3	Manufacturing (CMC)-Control		Label is not available on this site.
07/28/1993	SUPPL-2	Manufacturing (CMC)		Label is not available on this site.
07/26/1993	SUPPL-1	Labeling		Label is not available on this site.

Labels for NDA 050689

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/20/2024	SUPPL-27	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050689s027lbl.pdf
09/15/2021	SUPPL-26	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s026lbl.pdf
03/08/2021	SUPPL-25	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050689s025lbl.pdf
07/01/2015	SUPPL-22	Labeling-Package Insert	Label (PDF)	Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050689s022lbl.pdf
11/13/2014	SUPPL-18	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050689Orig1s018lbl.pdf
05/14/2008	SUPPL-16	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf
11/09/2001	SUPPL-11	Labeling	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50689s11s13lbl.pdf

Therapeutic Equivalents for NDA 050689

MYCOBUTIN

CAPSULE;ORAL; 150MG
TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
MYCOBUTIN	RIFABUTIN	150MG	CAPSULE;ORAL	Prescription	Yes	AB	050689	PFIZER
RIFABUTIN	RIFABUTIN	150MG	CAPSULE;ORAL	Prescription	No	AB	212430	I3 PHARMS
RIFABUTIN	RIFABUTIN	150MG	CAPSULE;ORAL	Prescription	No	AB	215041	NOVITIUM PHARMA

Top